{"version":"1.0","type":"link","title":"Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma.","author_name":"Ajani JA 외","author_url":"https://prs-insight.online/author/Ajani%20JA","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/88170","thumbnail_width":1200,"thumbnail_height":630}